Estimation of Infection Force of Hepatitis C Virus Among Drug Users in France

被引:6
作者
Kasereka, Selain [1 ]
Le Strat, Yann [2 ]
Leon, Lucie [2 ]
机构
[1] Univ Kinshasa, Kinshasa, DEM REP CONGO
[2] French Natl Publ Hlth Agcy, Sante Publ France, St Maurice, Ile De France, France
来源
RECENT ADVANCES IN NONLINEAR DYNAMICS AND SYNCHRONIZATION: WITH SELECTED APPLICATIONS IN ELECTRICAL ENGINEERING, NEUROCOMPUTING, AND TRANSPORTATION | 2018年 / 109卷
关键词
INJECT DRUGS; PEOPLE; PREVENTION; AUSTRALIA; MORTALITY;
D O I
10.1007/978-3-319-58996-1_15
中图分类号
TM [电工技术]; TN [电子技术、通信技术];
学科分类号
0808 ; 0809 ;
摘要
The spread of diseases is a dynamic and complex phenomenon. In the world, they are due to misery and poverty. To understand epidemiological systems is essential for governments. Since modeling simplifies reality, it is an excellent method. The hepatitis C virus (HCV) infection is common worldwide, and injection drug use remains the major mode of transmission of the disease, especially because of equipment sharing. Consequently, it is crucial to monitor the HCV transmission dynamics over time and to assess the effect of harm reduction measures. The aim of this work is to estimate the force of infection of hepatitis C from two national cross-sectional epidemiological surveys conducted in 2004 and 2011 by the French Institute for Public Health Surveillance and its partners in a drug user population in France. HCV prevalence was estimated according to age and calendar time through fractional polynomials adjusted or not to the HIV serological status and to injected drug users or oral drug users in general. The force of infection was modeled according to an SIS (susceptible-infected-susceptible) compartmental model using ordinary differential equations (ODE) and as a function of the derivative of the prevalence function depending on age, time, HIV serological status, and having injected at least once in their life, from 2000 to 2020. Our model was applied on real and simulated surveys using R and Stata software. The results show that HCV prevalence and the force of infection are linked to age and time, and are very high for drug users who injected at least once in their life and who are simultaneously HCV and HIV infected. Based on this model, we estimated that HCV incidence will continue to decline over the following years. Currently in France, there is no cohort study of the HCV among drug users. The only way to estimate HCV incidence in the French population is to use the only existing two national cross-sectional surveys. Our work provides guidance for researchers to compare several cross-sectional epidemiological surveys among drug users and proposes an alternative method to estimate the force of infection among drug users from cross-sectional surveys in the absence of a cohort.
引用
收藏
页码:319 / 344
页数:26
相关论文
共 50 条
  • [41] Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users?
    Kapadia, F
    Vlahov, D
    Des Jarlais, DC
    Strathdee, SA
    Ouellet, L
    Kerndt, P
    Morse, EV
    Williams, I
    Garfein, RS
    EPIDEMIOLOGY, 2002, 13 (06) : 738 - 741
  • [42] Seroepidemiology of Hepatitis C Among Drug Users at a Detoxification Center in Southeast China
    Zhang, Dangui
    Zhang, Xubin
    Xu, Lu
    Tyrrell, D. Lorne
    Houghton, Michael
    Ba-Thein, William
    HEPATITIS MONTHLY, 2020, 20 (03)
  • [43] Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users
    Major, Marian
    Gutfraind, Alexander
    Shekhtman, Louis
    Cui, Qingwen
    Kachko, Alla
    Cotler, Scott J.
    Hajarizadeh, Behzad
    Sacks-Davis, Rachel
    Page, Kimberly
    Boodram, Basmattee
    Dahari, Harel
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (449)
  • [44] Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
    Philip, Bruggmann
    Sarah, Blach
    Pierre, Deltenre
    Jan, Fehr
    Roger, Kouyos D.
    Daniel, Lavanchy
    Beat, Muellhaupt
    Andri, Rauch
    Homie, Razavi
    Patrick, Schmid
    David, Semela
    Marcel, Stoeckle
    Franco, Negro
    SWISS MEDICAL WEEKLY, 2017, 147
  • [45] Prevalence and risk factors for Hepatitis C viral infection amongst a cohort of Irish drug users attending a drug treatment centre for Agonist Opioid Treatment (AOT)
    Keegan, David
    Crowley, Des
    Laird, Eamon
    Van Hout, Marie Claire
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2017, 19 (01) : 45 - 54
  • [46] Low Incidences of Human Immunodeficiency Virus and Hepatitis C Virus Infection and Declining Risk Behaviors in a Cohort of Injection Drug Users in Chennai, India
    Solomon, Sunil Suhas
    Celentano, David D.
    Srikrishnan, Aylur K.
    Vasudevan, Canjeevaram K.
    Murugavel, Kalilapuri G.
    Iqbal, Syed H.
    Anand, Santhanam
    Kumar, Muniratnam Suresh
    Latkin, Carl
    Solomon, Suniti
    Mehta, Shruti H.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 172 (11) : 1259 - 1267
  • [47] Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs
    Zeiler, Irmgard
    Langlands, Trevor
    Murray, John M.
    Ritter, Alison
    DRUG AND ALCOHOL DEPENDENCE, 2010, 110 (03) : 228 - 233
  • [48] Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011-2013
    Brouard, C.
    Pillonel, J.
    Sogni, P.
    Chollet, A.
    Lazarus, J. V.
    Pascal, X.
    Barin, F.
    Jauffret-Roustide, M.
    EPIDEMIOLOGY AND INFECTION, 2017, 145 (06) : 1259 - 1269
  • [49] Risk Factors of Hepatitis C Virus Infection in Drug Users From Eleven Methadone Maintenance Treatment Clinics in Xi'an, China
    Wei Xiaoli
    Wang Lirong
    Wang Xueliang
    Li Jinsong
    Li Hengxin
    Jia Wei
    HEPATITIS MONTHLY, 2014, 14 (11)
  • [50] HIV infection and hepatitis C virus genotype 1 a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection
    Bartlett, Sofia R.
    Jacka, Brendan
    Bull, Rowena A.
    Luciani, Fabio
    Matthews, Gail V.
    Lamoury, Francois M. J.
    Hellard, Margaret E.
    Hajarizadeh, Behzad
    Teutsch, Suzy
    White, Bethany
    Maher, Lisa
    Dore, Gregory J.
    Lloyd, Andrew R.
    Grebely, Jason
    Applegate, Tanya L.
    INFECTION GENETICS AND EVOLUTION, 2016, 37 : 252 - 258